![](https://endpts.com/wp-content/uploads/2021/10/Mark-Foley-Revance-tile-scaled.jpg)
Mark Foley, Revance CEO (Revance via Vimeo)
Revance to be acquired for $900M+ as Botox trade secrets lawsuit continues
Revance Therapeutics, the maker of Botox competitor Daxxify, will be acquired for more than $900 million.
Crown Laboratories will buy out …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.